SLC10A7: A Potential Drug Target and Biomarker (G84068)

Target Name: SLC10A7

NCBI ID: G84068

SLC10A7

SLC10A7: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 10 (SLC10A7) is a gene that encodes a protein known as SLC10A7. As a member of the SLC family, SLC10A7 is responsible for transporting sodium and glucose across cell membranes. It is a critical protein that is expressed in many different tissues and cells throughout the body, including the brain, pancreas, and red blood cells.

Several studies have identified SLC10A7 as a potential drug target for various diseases, including diabetes, hypertension, and obesity. Its role as a drug target is based on its unique structure and the effects it has on various physiological processes in the body.

One of the key reasons why SLC10A7 is considered a potential drug target is its location on the body's cells. SLC10A7 is expressed in the brain, pancreas, and red blood cells, which are all critical organs that are involved in the regulation of glucose and sodium levels in the body. Therefore, any drug that targets SLC10A7 is likely to have a more targeted and effective effect on these organs.

Another reason why SLC10A7 is a promising drug target is its role in the regulation of glucose and sodium levels. SLC10A7 is involved in the reabsorption of glucose from the kidneys, which is critical for maintaining blood sugar levels. Additionally, SLC10A7 is involved in the regulation of sodium levels in the body, which is important for maintaining the proper functioning of the nervous system.

SLC10A7 has also been shown to be involved in the regulation of other physiological processes in the body, including inflammation and pain. These properties make it an attractive target for drugs that are designed to modulate inflammation, pain, and other biological processes in the body.

In addition to its potential as a drug target, SLC10A7 is also a potential biomarker for a number of diseases. Its expression has been shown to be elevated in a variety of diseases, including diabetes, obesity, and cancer. Additionally, SLC10A7 has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of these diseases.

Overall, SLC10A7 is a protein that has a significant impact on a variety of physiological processes in the body. Its potential as a drug target and biomarker make it an attractive target for researchers and pharmaceutical companies that are looking for new treatments for a range of diseases.

Protein Name: Solute Carrier Family 10 Member 7

Functions: Involved in teeth and skeletal development. Has an essential role in the biosynthesis and trafficking of glycosaminoglycans and glycoproteins, to produce a proper functioning extracellular matrix. Required for extracellular matrix mineralization (PubMed:30082715, PubMed:29878199). Also involved in the regulation of cellular calcium homeostasis (PubMed:30082715, PubMed:31191616). Does not show transport activity towards bile acids or steroid sulfates (including taurocholate, cholate, chenodeoxycholate, estrone-3-sulfate, dehydroepiandrosterone sulfate (DHEAS) and pregnenolone sulfate)

The "SLC10A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC10A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets